Jupiros-A 20mg/150mg Capsule is a combination pharmaceutical formulation containing Rosuvastatin 20mg and Aspirin 150mg, designed for the management of cardiovascular conditions. Rosuvastatin, a potent HMG-CoA reductase inhibitor, effectively lowers low-density lipoprotein cholesterol (LDL-C) and total cholesterol levels, thereby reducing the risk of atherosclerosis and related cardiovascular events. Aspirin, an antiplatelet agent, irreversibly inhibits cyclooxygenase-1 (COX-1), resulting in decreased thromboxane A2 production and subsequent inhibition of platelet aggregation. The combined action of these agents provides a dual therapeutic approach by addressing both lipid abnormalities and platelet-mediated thrombotic risks. Jupiros-A is indicated for patients at high risk of cardiovascular disease, including those with a history of myocardial infarction, stroke, or established peripheral arterial disease, as well as individuals requiring primary prevention of cardiovascular events. The fixed-dose combination enhances patient compliance by simplifying treatment regimens. Administration should be under medical supervision, considering contraindications such as active bleeding, hypersensitivity to aspirin or statins, and severe hepatic impairment. Regular monitoring of liver function tests, lipid profiles, and hematological parameters is recommended to ensure safety and therapeutic efficacy. Patients should be advised regarding potential side effects, including myopathy, gastrointestinal disturbances, and bleeding risks associated with aspirin use.